CraniUS Therapeutics Receives FDA 510(k) Clearance for Cranial Implant
CraniUS Therapeutics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CraniUS® Plate. This clearance marks the company's first product for the U.S. market.
CraniUS Therapeutics announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the CraniUS® Plate, a patient-specific cranial implant.
The clearance establishes the company's first product for the U.S. market and forms the foundation of its investigational NeuroPASS™ platform. The CraniUS® Plate is designed to repair or replace cranial bone defects, with its custom manufacturing process ensuring precise anatomical fit.
The FDA's 510(k) process evaluates a new medical device by comparing it to a legally marketed predicate device to determine its safety and effectiveness. The clearance for the CraniUS® Plate indicates it meets these regulatory standards.
This approval is expected to enable new clinical applications and support further development of the company's neurosurgery technology platform.